Explore

Trendline Trendline
Kanvas Biosciences Secures $48 Million to Advance Microbiome Therapeutics for Cancer Patients

Kanvas Biosciences Secures $48 Million to Advance Microbiome Therapeutics for Cancer Patients

Kanvas Biosciences Secures $48 Million to Advance Microbiome Therapeutics for Cancer Patients
Trendline Trendline
Kanvas Biosciences Secures $48M Series A to Advance Microbiome Therapeutics for Cancer Patients

Kanvas Biosciences Secures $48M Series A to Advance Microbiome Therapeutics for Cancer Patients

Kanvas Biosciences Secures $48M Series A to Advance Microbiome Therapeutics for Cancer Patients
Trendline Trendline
Kanvas Biosciences Secures $48M Series A Funding to Advance Microbiome Therapeutics for Cancer Patients

Kanvas Biosciences Secures $48M Series A Funding to Advance Microbiome Therapeutics for Cancer Patients

Kanvas Biosciences Secures $48M Series A Funding to Advance Microbiome Therapeutics for Cancer Patients
Trendline Trendline
Cytospire Secures $83 Million for Innovative T-Cell Engager Platform

Cytospire Secures $83 Million for Innovative T-Cell Engager Platform

Cytospire Secures $83 Million for Innovative T-Cell Engager Platform
Trendline Trendline
Cytospire Secures $83 Million for Innovative T-Cell Engager Platform Targeting Cancer

Cytospire Secures $83 Million for Innovative T-Cell Engager Platform Targeting Cancer

Cytospire Secures $83 Million for Innovative T-Cell Engager Platform Targeting Cancer
Trendline Trendline
Allarity Therapeutics Advances Stenoparib Manufacturing for Phase 3 Trials in Ovarian Cancer

Allarity Therapeutics Advances Stenoparib Manufacturing for Phase 3 Trials in Ovarian Cancer

Allarity Therapeutics Advances Stenoparib Manufacturing for Phase 3 Trials in Ovarian Cancer
Trendline Trendline
Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept
Trendline Trendline
Diakonos Oncology Receives FDA Fast Track Designation for Melanoma Treatment

Diakonos Oncology Receives FDA Fast Track Designation for Melanoma Treatment

Diakonos Oncology Receives FDA Fast Track Designation for Melanoma Treatment
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Trendline Trendline
Allarity Therapeutics Advances Stenoparib Toward Phase 3 Development for Ovarian Cancer

Allarity Therapeutics Advances Stenoparib Toward Phase 3 Development for Ovarian Cancer

Allarity Therapeutics Advances Stenoparib Toward Phase 3 Development for Ovarian Cancer
Trendline Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
Trendline Trendline
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates